Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

April 26, 2024

Kateryna Fedorov, MD, discusses considerations when deciding between quizartinib and midostaurin for patients with FLT3-mutated AML.

April 18, 2024

Patients with chronic lymphocytic leukemia who initiated therapy through an integrated health-system specialty pharmacy had high therapy adherence rates.

April 12, 2024

Somedeb Ball, MBBS, discusses the benefits of luspatercept for patients with anemia due to a myelodysplastic syndrome.

April 10, 2024

Bhagirathbhai Dholaria, MBBS, discusses the benefits and limitations of liso-cel for patients with relapsed/refractory chronic lymphocytic leukemia.

March 27, 2024

Speculation on the impact of large language models or artificial intelligence in the future of health care is commonplace, causing excitement and concern.

March 13, 2024

Brian I. Rini, MD, FASCO, shares the importance of the FDA approval of belzutifan in patients with advanced renal cell carcinoma.

March 01, 2024

Brian I. Rini, MD, FASCO, discusses the background that led to the FDA approval of belzutifan for patients with advanced renal cell carcinoma.

February 21, 2024

Brian I. Rini, MD, FASCO, discusses the research that led to the FDA approval of belzutifan for patients with advanced renal cell carcinoma.

February 20, 2024

Kathryn Beckermann, MD, PhD, discusses the treatment of PY314 in combination with pembrolizumab in patients with clear cell renal cell carcinoma.

February 19, 2024

Drs Kitko and Patel discuss graft-versus-host disease recognition, treatment selection, and ongoing research with novel agents and biomarkers of response.

February 01, 2024

Emily Arner, PhD, discusses research on the role of SETD2 loss in metastatic clear cell renal cell carcinoma ccRCC.

January 25, 2024

Bhagirathbhai Dholaria, MBBS, discusses the ongoing evaluation of noncovalent BTK inhibitors in patients with chronic lymphocytic leukemia.

January 24, 2024

As the treatment paradigm in urothelial cancer expands to include agents directed at various targets, NECTIN-4 has emerged as a promising treatment target.

December 27, 2023

Experts close the discussion by sharing insights on the future in advanced RCC, emphasizing the development of emerging agents and combination regimens for the treatment landscape.

December 27, 2023

Drs Rini and Hammers discuss additional clinical readouts from the 2023 IKCS: North America meeting including emerging agents for advanced RCC such as belzutifan and zanzalitinib.

December 23, 2023

It is never too early to think about interviewing for your next opportunity. Even if you have already committed to your next career move, learning how to interview will serve you well as you may be considered for different positions within the organization.

December 21, 2023

Brian I. Rini, MD, FASCO, discusses the significance of the FDA approval of belzutifan for the treatment of patients with advanced renal cell carcinoma

December 20, 2023

Brian Rini, MD, discusses the impact of real-world outcomes on treatment selection, highlighting frontline combination axitinib plus pembrolizumab in advanced RCC.

December 20, 2023

A comprehensive discussion on toxicity management and patient tolerability for combination regimens in the setting of advanced RCC.

December 13, 2023

Brian Rini, MD, and Hans Hammers, MD, PhD, discuss the evolution of management for advanced renal cell carcinoma (RCC), noting the role of biomarkers and its use in practice.